Risankizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Disease
Conditions
Inflammatory Bowel Disease
Trial Timeline
Apr 24, 2024 → Feb 5, 2026
NCT ID
NCT06346288About Risankizumab
Risankizumab is a approved stage product being developed by AbbVie for Inflammatory Bowel Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06346288. Target conditions include Inflammatory Bowel Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03914261 | Pre-clinical | Completed |
| NCT06946524 | Phase 1 | Completed |
| NCT06937619 | Phase 1 | Completed |
| NCT06571266 | Phase 1 | Completed |
| NCT06346288 | Approved | Completed |
| NCT06054425 | Phase 1 | Completed |
| NCT05283135 | Phase 2 | Completed |
| NCT04862286 | Phase 3 | Active |
| NCT05274087 | Phase 1 | Completed |
| NCT04102007 | Phase 3 | Completed |
| NCT03875508 | Phase 3 | Completed |
| NCT03047395 | Phase 3 | Completed |
| NCT03022045 | Phase 3 | Completed |
| NCT02986373 | Phase 2 | Completed |
| NCT02203851 | Phase 2 | Completed |
Competing Products
20 competing products in Inflammatory Bowel Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 85 |
| CT-P13 | Celltrion | Phase 3 | 77 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 23 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 77 |
| fidaxomicin | Astellas Pharma | Approved | 85 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 52 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 33 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 52 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 33 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 52 |
| MORF-057 | Eli Lilly | Phase 2 | 52 |
| LY3009104 | Eli Lilly | Phase 1 | 33 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 33 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 33 |
| Human Papillomavirus Vaccine | Merck | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Gardasil vaccine | Merck | Pre-clinical | 23 |
| Bezlotoxumab | Merck | Approved | 85 |